Addex Therapeutics Ltd Logo

Addex Therapeutics Ltd

ADXN | SW

Overview

Corporate Details

ISIN(s):
CH0029850754 (+2 more)
LEI:
89450068Y9KVP2MQGH86
Country:
Switzerland
Address:
c/o Addex Pharma SA, Chemin des Aulx 12, 1228 Plan-Les-Ouates
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Addex Therapeutics Ltd is a clinical-stage pharmaceutical company that focuses on the development and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of drugs known as allosteric modulators, which are designed to treat neurological disorders. Leveraging its proprietary drug discovery platform, Addex develops a portfolio of innovative therapies aimed at modulating receptors and other proteins that are considered attractive targets for treating various central nervous system conditions.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Addex Therapeutics Ltd. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-30 02:00
Related Party Transaction
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine …
English 7.3 KB
2025-06-25 02:00
Post-Annual General Meeting Information
Addex Shareholders Approve All Resolutions at Annual General Meeting
English 5.6 KB
2025-06-19 02:00
Earnings Release
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Upd…
English 13.7 KB
2025-06-18 02:00
Report Publication Announcement
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Cal…
English 5.9 KB
2025-06-06 02:00
Regulatory News Service
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple…
English 7.4 KB
2025-06-05 02:00
Regulatory News Service
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cou…
English 6.4 KB
2025-06-03 02:00
Pre-Annual General Meeting Information
Addex Convenes Annual General Meeting 2025
English 6.8 KB
2025-05-12 02:00
Regulatory News Service
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Suc…
English 6.6 KB
2025-01-08 01:00
Regulatory News Service
Addex to Present at the 2025 Swiss Equities Baader Conference
English 5.2 KB
2024-11-22 01:00
Earnings Release
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
English 17.7 KB
2024-11-11 01:00
Report Publication Announcement
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second…
English 7.1 KB
2024-09-30 02:00
Earnings Release
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results …
English 17.2 KB
2024-09-19 02:00
Earnings Release
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net…
English 7.0 KB
2024-09-04 02:00
Regulatory News Service
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Confe…
English 5.2 KB
2024-08-27 02:00
M&A Activity
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Mo…
English 7.4 KB

Automate Your Workflow. Get a real-time feed of all Addex Therapeutics Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Addex Therapeutics Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-11-27 N/A Executive member Buy None 301,345.00 CHF
2023-11-27 N/A Executive member Buy None 53,760.00 CHF
2023-11-27 N/A Executive member Buy None 45,450.00 CHF
2023-11-27 N/A Non-Executive member Buy None 44,856.00 CHF
2023-11-27 N/A Non-Executive member Buy None 24,423.00 CHF
2023-11-27 N/A Executive member Buy None 5,487.00 CHF
2023-11-27 N/A Non-Executive member Buy None 3,927.00 CHF
2023-11-27 N/A Executive member Buy None 2,150.00 CHF

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Adocia Logo
Developing novel drug formulations for metabolic diseases like diabetes and obesity for out-licensing.
France ADOC